Comparison of three topical treatments (Minoxidil, Clascoterone, and Dutasteride lotions) for hair regrowth in men with male pattern baldness

A Randomized Assessor-Blinded Parallel-Group Trial Comparing Topical Clascoterone 1 Percent versus Topical Dutasteride solution versus Topical Minoxidil 5 Percent in Male Androgenetic Alopecia - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113515

Enrollment

105

Registered

2026-07-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified

Interventions

Intervention1: Topical minoxidil 5% lotion: Topical Minoxidil 5% lotion, 1 mL applied twice daily over affected scalp for 24 weeks Intervention2: Topical Dutasteride 0.0025% lotion lotion: Topical Dut

Eligibility

Inclusion criteria

Inclusion criteria: Male patients aged 18 50 years Clinical diagnosis of androgenetic alopecia (Norwood Hamilton Grade II V) Willingness to provide written informed consent Willingness to comply with study protocol and follow-up visits

Exclusion criteria

Exclusion criteria: Clinical diagnosis of androgenetic alopecia (Norwood Hamilton Grade 1,6,7) Not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
Change in hair density and diameter (hairs/cm ) from baseline to 24 weeks, assessed Trichoscopy (Fotofinder, fixed 1 cm target area)Timepoint: 0,4,8,12,16,20,24 weeks	—

Secondary

Measure	Time frame
Global photographic assessment (GPA) score at 24 weeks Patient satisfaction score (Likert scale) Incidence of adverse events (local and systemic)Timepoint: 0,4,8,12,16,20,24 weeks	—

Countries

India

Contacts

Public ContactDr Vikas Shankar

Patna Medical College

drabhijeetjha@gmail.com09631444797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026